Refractory reflux disease. What kind of drug therapy and for how long? When to operate? [Therapieresistente Refluxkrankheit : Wie und Wie Lange Medikamentös Therapieren? Wann Operieren?]

被引:0
作者
Labenz J. [1 ]
Feuner H. [2 ]
机构
[1] Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus, Siegen 57074
[2] Chirurgische Klinik und Poliklinik, TU München, München
来源
Der Gastroenterologe | 2009年 / 4卷 / 5期
关键词
Fundoplication; Gastro-esophageal reflux disease; Lifestyle measures; Proton pump inhibitor; Therapy-resistant heartburn;
D O I
10.1007/s11377-009-0290-6
中图分类号
学科分类号
摘要
Gastro-esophageal reflux disease (GERD) is common. Standard treatment includes lifestyle measures and proton pump inhibitors (PPIs). GERD is considered to be refractory to treatment when a standard dose of PPI fails to sufficiently control symptoms within 8 weeks. Severe reflux esophagitis may require a longer period of treatment. In the event of therapy-resistant GERD, a stratified approach is needed if diagnostic errors and therapeutic confusion are to be avoided. Major stumbling blocks are misdiagnosis, inadequate acid suppression, and a pathophysiological situation in which acid plays only a minor role. When other potential esophageal or extra-esophageal causes have been excluded, the first step is to optimise acid inhibition measures. If problems nevertheless persist, a functional diagnostic workup is indicated, preferably using a combination of pH-metry and impedance monitoring. Depending on the outcome, the therapeutic options that are then most likely to be useful are intensification and optimisation of the antisecretory treatment, measures aimed at relaxing the lower esophageal sphincter, modulation of esophageal sensitivity, and surgical reconstruction of the gastro-esophageal antireflux barrier. © 2009 Springer Medizin Verlag.
引用
收藏
页码:393 / 402
页数:9
相关论文
共 39 条
[1]  
Becker V., Bajbouj M., Waller K., Et al., Clinical trial: Persistent gastro-oesophageal symptoms despite standard therapy with proton pump inhibitors - A follow-up study of intraluminal- impedance guided therapy, Aliment Pharmacol Ther, 26, (2007)
[2]  
Broekaert D., Fischler B., Sifrim D., Et al., Influence of Citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: A double-blind, placebo controlled study, Aliment Pharmacol Ther, 23, (2006)
[3]  
Boeckxstaens G.E.E., Review article: The pathophysiology of gastro-oesophageal reflux disease, Aliment Pharmacol Ther, 26, (2007)
[4]  
Bytzer P., Jones R., Vakil N., Et al., Evaluation of the proton pump inhibitor (PPI) test for the diagnosis of GERD: Results from the Diamond study, Gastroenterology, 134, SUPPL. 1, (2008)
[5]  
Catarci M., Gentileschi P., Papi C., Et al., Evidence-based appraisal of antireflux fundoplication, Ann Surg, 239, (2004)
[6]  
Chiba N., De Gara C.J., Wilkinson J.M., Hunt R.H., Speed of healing and symptom relief in grade lito IV gastroesophageal reflux disease: A meta-analysis, Gastroenterology, 112, (1997)
[7]  
Crowell M.D., Bradley A., Hansel S., Et al., Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux, Am J Gastroenterol, 104, (2009)
[8]  
Dent J., Microscopic esophageal mucosal injury in nonerosive reflux disease, Clin Gastroenterol Hepatol, 5, (2007)
[9]  
Dickman R., Schiff E., Hollan A., Et al., Clinical trial: Acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn, Aliment Pharmacol Ther, 26, (2007)
[10]  
Donnellan C., Sharma N., Preston C., Moayyedi P., Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease, Cochrane Database Syst Rev, 18, 2, (2005)